FindTrial
Sign In

Vixarelimab

DRUG5 trials

Sponsors

Genentech Inc., Genentech, Inc.

Conditions

Idiopathic Pulmonary FibrosisModerate to Severe Ulcerative ColitisPrurigo NodularisPruritisSystemic Sclerosis With Lung InvolvementSystemic Sclerosis-Associated Interstitial Lung DiseaseUlcerative Colitis

Phase 1

A Study to Evaluate the Activity, and Safety of Vixarelimab in Participants With Moderate to Severe Active Ulcerative Colitis
Active, not recruitingNCT06693908
Genentech, Inc.Moderate to Severe Ulcerative Colitis
Start: 2025-03-31End: 2026-08-18Updated: 2026-07-16

Phase 2

Study to Assess the Efficacy, Safety, and Tolerability of Vixarelimab in Reducing Pruritus in Prurigo Nodularis
CompletedNCT03816891
Genentech, Inc.Prurigo Nodularis, Pruritis
Start: 2019-03-11End: 2023-08-24Updated: 2026-01-13
A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease
TerminatedNCT05785624
Genentech, Inc.Idiopathic Pulmonary Fibrosis, Systemic Sclerosis With Lung Involvement
Start: 2023-05-26End: 2026-01-12Updated: 2026-02-09
A Two-Cohort, Phase II, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Evaluating the Efficacy and Safety of Vixarelimab Compared with Placebo in Patients with Idiopathic Pulmonary Fibrosis and in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease
CompletedCTIS2022-502828-42-00
Genentech Inc.Idiopathic Pulmonary Fibrosis, Systemic Sclerosis-Associated Interstitial Lung Disease
Start: 2023-09-01End: 2025-12-18Target: 101Updated: 2025-10-21
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Participants With Moderate to Severe Ulcerative Colitis (UC)
TerminatedNCT06137183
Genentech, Inc.Ulcerative Colitis
Start: 2024-05-01End: 2025-06-16Updated: 2026-02-24

Related Papers

Vixarelimab in Patients With Prurigo Nodularis: A Randomized Clinical Trial.
2025-12-17
Impact of Obesity on the Structured Histopathology of Chronic Rhinosinusitis Patients.
2025-10-06
P0929 Design and rationale for the phase 1c study evaluating the pharmacodynamic (PD) effects of vixarelimab in patients with Ulcerative Colitis (UC)
Journal of Crohn s and Colitis2025-01-01
Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor β antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a study.
2023-02-0356 citations
Prurigo nodularis: Studie mit Vixarelimab zeigt vielversprechende Ergebnisse mit neuen Ansätzen
Kompass Dermatologie2023-01-01